

APASL
2018

APASL 2018

27th
Annual Conference of the
Asian Pacific Association for
The Study of the Liver

Hepatology - The Next Genre

March 14-18, 2018
The Ashok, New Delhi, India



Tentative Scientific Program

Day 1 March 14, 2018		
APASL Research Methodology Workshop		
Day 2 March 15, 2018		
08:00-10:00 hrs	Postgraduate Course I-General hepatology Session: Viral Hepatitis: Difficult treatment decisions [15 min] Nonresponse/Relapse on DAAs for HCV infection [15 min] Treatment of hepatitis C in CKD patients [15 min] Discussion [10 min] Chronic hepatitis E [15 min] Hepatitis due to non-hepatotropic viruses [15 min] Discussion [10 min]	Hall A
10:00-10:30 hrs	Coffee Break	
10:30-12:00 hrs	Postgraduate Course I-General hepatology Session: Alcoholic liver disease and Non-alcoholic fatty liver disease Noninvasive assessment of fat and inflammation in NAFLD [15 min] Cirrhosis with diabetes [15 min] Discussion [10 min] Liver histology as predictor of response to treatment in alcoholic hepatitis [15 min] Management of severe alcoholic hepatitis beyond steroids [15 min] Discussion [10 min]	Hall A
12:00-13:00 hrs	Postgraduate Course I-General hepatology Session: Challenges in Hepatology Management of septic shock in cirrhosis [Diagnosis, choice of fluids and vasopressors] [12 min] Discussion [3 min] Difficult to treat SBP [12 min] Discussion [3 min] Sarcopenic obesity in cirrhosis [12 min] Discussion [3 min]	Hall A

APASL
2018

APASL 2018

27th
Annual Conference of the
Asian Pacific Association for
The Study of the Liver

Hepatology - The Next Genre

March 14-18, 2018
The Ashok, New Delhi, India



	Liver biopsy in cirrhosis: useful or not [Debate –YES/NO] [7 min + 7 min + 2 min rebuttal]	
13:00-14:30 hrs	Inauguration, Lunch symposium, Lunch	
14:30-15:30 hrs	Postgraduate Course I-General hepatology Session: Prescriptions in Liver Diseases Anticoagulants in cirrhosis [10 min] Discussion [3 min] Analgesics and antipyretics in cirrhosis [10 min] Discussion [3 min] ATT in decompensated cirrhosis [10 min] Discussion [3 min] PPI in cirrhosis- Debate [YES/NO] [7 min + 7 min + 2 min rebuttal] Discussion [4 min]	Hall A
15:30-16:30 hrs	Postgraduate Course I-General hepatology Session: Prescriptions in Liver Diseases Pathogenesis and new management options for symptomatic PHG and GAVE in cirrhosis [15 min] Discussion [5 min] Refractory Hepatic encephalopathy [15 min] Discussion [5 min] Algorithmic Management of Hyponatremia and Hypernatremia in cirrhosis [15 min] Discussion [5 min]	Hall A
16:30-17:00 hrs	Coffee Break	
17:00-18:00 hrs	Postgraduate Course I-General hepatology Session: Liver failure DILI in cirrhosis: diagnosis and management [15 min] Discussion [5 min] Acute severe autoimmune hepatitis [15 min] Discussion [5 min] Newer non-transplant options in acute liver failure [15 min]	Hall A
18:00-19:00 hrs	Evening symposiums	

APASL
2018

APASL 2018

27th
Annual Conference of the
Asian Pacific Association for
The Study of the Liver

Hepatology - The Next Genre

March 14-18, 2018
The Ashok, New Delhi, India



Day 3 | March 16, 2018

08:00-09:00 hrs	<p>Viral Hepatitis B-Session 1: Hepatitis B- Clinical challenges Key note address: Treatment of chronic hepatitis B : beyond guidelines [20 min]</p> <p>Case 1 [20 min]</p> <p>Plenary clinical oral paper: [10 min + 5 min]</p>	Hall A
08:00-09:00 hrs	<p>Hepatic encephalopathy Session 1: Hepatic encephalopathy in cirrhosis</p> <p>Brain Reserve in Cirrhosis and its relation with Encephalopathy [15 min + 5 min]</p> <p>Hepatic Parkinsonism: Diagnosis and Management [15 min + 5 min]</p> <p>Treatment of Refractory Hepatic Encephalopathy in Cirrhosis [15 min + 5 min]</p>	Hall B
09:00-10:00 hrs	<p>Viral Hepatitis C-Session 1: Clinical Challenges in HCV Treatment</p> <p>Key note address: Treatment of HCV Genotype 3 in Cirrhosis: beyond guidelines [20 min]</p> <p>Case [20 min]</p> <p>Plenary clinical oral [10 min + 5 min]</p>	Hall A
09:00-10:00 hrs	<p>Cholestatic Liver Disease - Session 1: Pathophysiology of Cholestasis and Cholestatic Liver diseases</p> <p>Primary biliary Cholangitis: Genes, Gut and Environment [15 min + 5 min]</p> <p>Spectrum and cellular basis of Non-PBC/PSC Cholestatic Liver Diseases in Adults [15 min + 5 min]</p> <p>Cholestasis in sepsis-Pathogenesis and management options [15 min + 5 min]</p>	Hall B
10:00-10:30 hrs	Coffee Break	
10:30-11:30 hrs	<p>NAFLD Session 1: NAFLD as a Systemic Disease Keynote Address: Hepatic fat content reflective of systemic inflammation and injury? [20 min]</p> <p>Case [20 min]</p> <p>Diabetes is a Liver Disease [Debate-Yes/No] [7 min + 7 min + 2 min rebuttal]</p> <p>Discussion [4 min]</p>	Hall A
11:30-12.30 hrs	<p>Liver Fibrosis-Session 1: Pathogenesis of liver fibrosis State of the Art Lecture:</p>	Hall A

APASL
2018

APASL 2018

27th
Annual Conference of the
Asian Pacific Association for
The Study of the Liver

Hepatology - The Next Genre

March 14-18, 2018
The Ashok, New Delhi, India



	<p>Do cellular mechanisms define location of hepatic fibrosis [pericellular, periportal, perivenular]? [20 min]</p> <p>Distinctive mechanisms of fibrogenesis in chronic cholestasis [15 min]</p> <p>Discussion: [5 min]</p> <p>Plenary basic oral [10 min + 5 min]</p>	
13:00-14:30 hrs	Lunch + Lunch Symposium	
14:30-15:30 hrs	<p>Drug Induced Liver Injury-Session 1: Spectrum of DILI Drug [Non Paracetamol] induced ALF [15 min + 5 min]</p> <p>The Spectrum and Management of Drug-Induced Acute Liver Injury in Chronic Liver Disease [15 min + 5 min]</p> <p>Prognostic Markers of Outcomes in DILI: Cellular, Biochemical and Histopathological [15 min + 5 min]</p>	Hall A
15:30-16:30 hrs	<p>Alcoholic liver disease- Session 1: Global Alliance on Alcoholic Liver Disease</p> <p>Global trends in the epidemiology of alcoholic liver disease [15 min + 5 min]</p> <p>Infections in Alcoholic Liver Disease [15 min + 5 min]</p> <p>Alcoholic Liver Disease: High Risk or Low Risk for Developing Hepatocellular Carcinoma? [15 min + 5 min]</p>	Hall A
16:30-17:00 hrs	Tea Break	
17:00-18:00 hrs	<p>Portal Hypertension, coagulation and Variceal Bleed- Session 1: Screening, prophylaxis and management of bleeding in Liver diseases</p> <p>Management of non-variceal bleed in a portal hypertensive cirrhotic [15 min + 5 min]</p> <p>Management of refractory variceal bleeding in advanced cirrhosis [15 min + 5 min]</p> <p>Novel Targets and Therapies for the prevention and reversal of portal hypertension in nonviral cirrhosis [15 min + 5 min]</p>	Hall A
18:00-19:00 hrs	<p>Hepatocellular carcinoma - Session 1: Pathogenesis and diagnosis of HCC</p> <p>Molecular classification of HCC: Are they already applicable in the clinical practice? [15 min + 5 min]</p> <p>Pathogenesis and potential drug targets of HCC in lean and obese NAFLD Typical and atypical radiological features of HCC and assessment criteria for treatment response to radiological interventions</p>	Hall A
20:00-22:00 hrs	Evening Symposium and Gala Dinner	

APASL
2018

APASL 2018

27th
Annual Conference of the
Asian Pacific Association for
The Study of the Liver

Hepatology: The Next Genre

March 14-18, 2018
The Ashok, New Delhi, India



Day 4 | March 17, 2018

08:00-09:00 hrs	<p>Viral Hepatitis B-Session 2: Hepatitis B-Pathogenesis and new diagnostic tools</p> <p>State of art lecture: New markers [HBV RNA, Core antigen, mi RNA, ccc DNA and others] in HBV: ready for clinical practice? [20 min]</p> <p>Viral and host mechanisms in reactivation of hepatitis B.[15 min] Discussion [5 min]</p> <p>Plenary basic oral paper: [10 min + 5 min]</p>	Hall A
08:00-09:00 hrs	<p>Hepatic regenerative medicine-Session 1: Non-transplant approaches in a Failing Liver</p> <p>State of art lecture: Pathophysiological basis and cellular targets for regeneration of cirrhotic liver [20 min]</p> <p>Tools of Tissue Engineering and clinical applications in liver [15 min + 5 min]</p> <p>Bile acids and liver regeneration: mechanism and clinical applications [15 min + 5]</p>	Hall B
09:00-10:00 hrs	<p>Viral hepatitis C-Session 2: HCV drug resistance and co-infections</p> <p>State for the art lecture: Viral and host mechanisms for failure of DAAs in HCV Genotype 3 infection and strategies to overcome it. [20 min]</p> <p>Management of HCV-HIV co-infection [10 min] Discussion [2 min]</p> <p>Management of HCV-HDV-HBV co-infection [10 min] Discussion [2 min]</p> <p>Plenary basic oral [10 min + 5 min]</p>	Hall A
09:00-10:00 hrs	<p>Hepatic Encephalopathy Session 2: Hepatic Encephalopathy in Acute Liver failure and Acute on Chronic Liver Failure</p> <p>State of Art Lecture: Neuroinflammation in Hepatic Encephalopathy [20 min]</p> <p>Hepatic Encephalopathy in Acute on Chronic Liver Failure [15 min + 5 min]</p> <p>Ammonia Targetted Therapy for Hepatic Encephalopathy in Acute Liver failure and Acute on Chronic Liver Failure [Debate-YES/NO] [7+7+2] [Discussion-4 min]</p>	Hall B
10:00-10:30 hrs	Coffee Break	
10:30-11:30 hrs	NAFLD- Session 2: Pathogenesis, Epidemiology and Natural History of NAFLD	Hall A

APASL
2018

APASL 2018

27th
Annual Conference of the
Asian Pacific Association for
The Study of the Liver

Hepatology - The Next Genre

March 14-18, 2018
The Ashok, New Delhi, India



	<p>State of the Art Lecture: Molecular and Cellular Mechanisms for Reversal of NASH [20 min]</p> <p>Functional relevance of Distribution(Subcutaneous vs Visceral vs Ectopic) and type (White vs Brown) of Fat in NAFLD.[15 min] Discussion: [5 min]</p> <p>Plenary basic oral [10 min + 5 min]</p>	
10:30-11:30 hrs	<p>Autoimmune liver Disorders- Session1: Pathogenesis and Diagnosis of Autoimmune liver Disorders</p> <p>New insights in Immunopathogenesis of Autoimmune hepatitis [15 min + 5 min]</p> <p>Drug and Virus induced Noncholestatic Autoimmune Liver Diseases [15 min +5 min]</p> <p>New Noninvasive Markers for Diagnosing Autoimmune Hepatitis: Can they replace Liver Biopsy [Debate-YES/NO][7+7+2] [Discussion-4 min]</p>	Hall B
11:30-12.30 hrs	<p>Drug Induced Liver Injury-Session 2: Tuberculosis in Cirrhosis-Case Scenarios</p> <p>Extrapulmonary Tuberculosis in a Cirrhotic-Spectrum and Diagnosis[Case Based]</p> <p>ATT in Advanced Cirrhosis [Case Based][Ashok]</p> <p>Post Liver Transplant Tuberculosis [Case based]</p>	Hall A
13:00-14:30 hrs	<p>Lunch + Lunch Symposium Lunch Symposium</p> <p>Session: Non-invasive assessment of liver fibrosis Lunch Symposium [17th]</p> <p>Can serum markers diagnose intermediate stages of fibrosis? Reliability of Ultrasound and MR based noninvasive methods of assessment of Liver Fibrosis.</p> <p>Debate: Liver Biopsy is still the gold standard for Liver Fibrosis assessment [Yes/No]</p>	Hall A
14:30-15:30 hrs	<p>Alcoholic liver disease- Session 2: Diagnosis and Treatment of ALD</p> <p>Treatment end points in severe alcoholic hepatitis [15 min + 5 min]</p> <p>Baseline and on therapy predictors (including metabolomics) of severity and response to therapy in severe alcoholic hepatitis [15 min + 5 min]</p> <p>Coexistence of alcoholic liver disease and alcoholic pancreatitis: challenges in management [15 min + 5 min]</p>	Hall A

APASL
2018

APASL 2018

27th
Annual Conference of the
Asian Pacific Association for
The Study of the Liver

Hepatology - The Next Genre

March 14-18, 2018
The Ashok, New Delhi, India



14:30-15:30 hrs	<p>Session: Mixed and rare Liver Tumors-Diagnosis and Management Hepatocolangiocarcinoma-Diagnosis and Management [15 min + 5 min]</p> <p>Intrahepatic cholangiocarcinoma- Diagnosis and Management [15 min + 5 min]</p> <p>Metastatic Neuroendocrine Tumor to Liver: Algorithmic Management Approach [15 min + 5 min]</p>	Hall B
14:30-17:00 hrs	<p>APASL-AASLD Symposium on Alcoholic Liver Disease</p> <p>Approaches to reverse gut dysbiosis and intestinal inflammation in alcoholic hepatitis [15 min]</p> <p>New biomarkers of infection and sepsis in severe alcoholic hepatitis [15 min]</p> <p>Non viral liver cancers in alcoholic liver disease [15 min]</p> <p>Micro-RNA in alcoholic hepatitis [15 min]</p> <p>Management options for steroid ineligible severe alcoholic hepatitis [15 min]</p> <p>Management of Malnutrition and sarcopenia in alcoholic liver disease: novel therapeutic targets [15 min]</p> <p>Discussion [30 min]</p>	Hall B
15:30-16:30 hrs	<p>Portal Hypertension, coagulation and Variceal Bleed- Session 2:Coagulation, thrombosis and vascular liver diseases</p> <p>Portal Vein Thrombosis in Cirrhosis: Risk Assessment and Algorithmic Management [15 min + 5 min]</p> <p>Acute HVOTO in cirrhotic- Conservative management or liver transplant [Debate] [7+7+2] [Discussion-4 min]</p> <p>Non cirrhotic portal hypertension: Eastern and Western Perspectives: Point of View [7+7]]Discussion-4 min]</p>	Hall A
15:30-16:30 hrs	<p>Cholestatic Liver Disease - Session 2: Diagnosis and Management of Cholestatic liver diseases</p> <p>Case Discussion: R K Jain [IgG4]</p> <p>Newer therapies for hepatic cholestasis: FXR, PXR and beyond [15 min + 5 min]</p> <p>Management of dominant strictures in PSC [15 min + 5 min]</p>	Hall B

APASL
2018

APASL 2018

27th
Annual Conference of the
Asian Pacific Association for
The Study of the Liver

Hepatology - The Next Genre

March 14-18, 2018
The Ashok, New Delhi, India



16:30-17:00 hrs	Tea Break	
17:00-18:00 hrs	<p>Hepatocellular carcinoma - Session 2: Staging and Management of HCC</p> <p>Staging of HCC-Which staging system correlates best with treatment options and clinical outcomes-East or West [Debate] [7+7+2] [Discussion-4 min]</p> <p>Treatment options for HCC with Main Portal Vein Thrombosis [Drugs, Interventional radiology, Radiation therapy and Surgical Management] [15 min + 5 min]</p> <p>Second-Line Treatment [post sorafenib] in Patients With Advanced Hepatocellular Carcinoma [15 min + 5 min]</p>	Hall A
18:30-19:30 hrs	Evening Symposium	
20:00-22:00 hrs	Gala Dinner	

Day 5 March 18, 2018		
08:00-09:00 hrs	<p>Viral hepatitis B- Session 3: HBV in special situations Management of HBV infection in a pregnant female [12 min] Discussion: [3 min]</p> <p>Management of HBV-HIV co-infection [12 min] Discussion: [3 min]</p> <p>Chronic HBV infection in children < 12 years [12 min] Discussion: [3 min]</p> <p>Debate: HBeAg chronic hepatitis B on antiviral therapy: Lifelong or on-demand [7 min + 7 min + 2 min rebuttal] Discussion [4 min]</p>	Hall A
09:00-10:00 hrs	<p>NAFLD Session 3: Targeted drug therapies for NAFLD: are we there? Gut targeted therapies in NAFLD [10 min]</p> <p>Liver and Kidney targeted therapies in NAFLD [10 min] Medications targeting oxidative stress and inflammation in NAFLD [10 min]</p> <p>Antifibrotic medications in NAFLD [10 min]</p> <p>Discussion: [20 min]</p>	Hall A
09:00-10:00 hrs	<p>Autoimmune liver Disorders- Session 2: Management of Autoimmune liver Disorders</p> <p>Managing Autoimmune hemolytic anemia in Liver diseases [15 min + 5 min]</p>	Hall B

APASL
2018

APASL 2018

27th
Annual Conference of the
Asian Pacific Association for
The Study of the Liver

Hepatology - The Next Genre

March 14-18, 2018
The Ashok, New Delhi, India



	Non-T Cell targets for treatment of Autoimmune Hepatitis [15 min + 5 min]	
	Overlap syndromes- Spectrum, Diagnosis and Management [15 min + 5 min]	
10:00-10:30 hrs	Coffee Break	
10:30-11:30 hrs	Alcoholic liver disease- Session 3: Management of Severe alcoholic hepatitis Emerging Targeted Drug Therapies for Severe Alcoholic hepatitis-Approaches and therapeutic targets [15 min + 5 min] Fecal microbiota transplant in severe alcoholic hepatitis [15 min + 5 min] Nutritional interventions change clinical outcomes in severe alcoholic hepatitis – Debate [YES/NO] [7+7+2] [Discussion-4 min]	Hall A
10:30-11:30 hrs	Hepatic regenerative medicine- Session 2: Cell therapies in liver diseases Exogenous Growth factors therapy for hepatic regeneration: beyond G-CSF [15 min + 5 min] Mesenchymal stem cells as a new therapeutic strategy for liver diseases [15 min + 5 min] Monocyte-Macrophages: potential clinical applications in liver regeneration [15 min + 5 min]	Hall B
11:30-12.30 hrs	Hepatocellular carcinoma - Session 3: Novel Therapeutic targets for HCC Liver Cancer Stem Cells- Characterization and a Target for prevention and treatment of HCC [15 min + 5 min] Immunotherapy of HCC-Rationale and case selection [15 min + 5 min] Current status of immune checkpoint inhibitors and their combinations in the treatment of HCC [15 min + 5 min]	Hall A